SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001567619-21-018222
Filing Date
2021-10-12
Accepted
2021-10-12 17:15:54
Documents
2
Period of Report
2021-10-11

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 1708
2 poa_harsch.htm EX-24 8271
  Complete submission text file 0001567619-21-018222.txt   11418
Mailing Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080
Business Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080 415-505-0809
Satsuma Pharmaceuticals, Inc. (Issuer) CIK: 0001692830 (see all company filings)

IRS No.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK REHOVOT L3 76704
Business Address
Harsch Mutya (Reporting) CIK: 0001727809 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39041 | Film No.: 211319368